US 11,964,028 B2
RNA nanoparticles and method of use thereof
Peixuan Guo, Columbus, OH (US); Hui Li, Columbus, OH (US); and Wei Luo, Lexington, KY (US)
Assigned to UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, Lexington, KY (US)
Filed by UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, Lexington, KY (US)
Filed on Nov. 9, 2020, as Appl. No. 17/093,038.
Application 17/093,038 is a division of application No. 15/566,972, granted, now 10,828,381, previously published as PCT/US2016/028012, filed on Apr. 17, 2016.
Claims priority of provisional application 62/150,233, filed on Apr. 20, 2015.
Claims priority of provisional application 62/149,117, filed on Apr. 17, 2015.
Prior Publication US 2022/0047728 A1, Feb. 17, 2022
Int. Cl. C07H 21/02 (2006.01); A61K 51/04 (2006.01); A61K 51/12 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01); C12N 15/115 (2010.01); B82Y 5/00 (2011.01)
CPC A61K 51/0491 (2013.01) [A61K 51/12 (2013.01); A61P 35/00 (2018.01); C12N 15/113 (2013.01); C12N 15/115 (2013.01); B82Y 5/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/16 (2013.01); C12N 2310/3517 (2013.01); C12N 2310/3519 (2013.01); C12N 2310/52 (2013.01)] 26 Claims
 
1. A method of diagnosing cancer in a subject, the method comprising administering to the subject an RNA dendrimer molecule, wherein the RNA dendrimer molecule comprises (a) a central core multi-branched RNA junction motif, wherein the central core motif comprises a plurality of branches, wherein a branch comprises at least one RNA oligonucleotide, and wherein the central core motif comprises at least one RNA oligonucleotide having at least 90% identity to SEQ ID NO: 12 (SquareE); and (b) an outer surface multi-branched RNA junction motif comprising at least one repeating multi-branched RNA junction motif unit, wherein the repeating unit comprises a plurality of branches, and wherein a branch comprises at least one RNA oligonucleotide, wherein the RNA dendrimer molecule comprises at least one imaging module, wherein the RNA dendrimer molecule comprises a folate receptor targeting module, wherein the cancer comprises a cancer that overexpresses folate receptor, and diagnosing the subject as having cancer if the RNA dendrimer molecule is detected in the subject.